GALECTIN THERAPEUTICS INC. Lease Obligation Incurred
GALECTIN THERAPEUTICS INC. (GALT) reported Lease Obligation Incurred of $127.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. lease obligation incurred for the quarter ending 2026-06-30 was $127.00K.
- GALECTIN THERAPEUTICS INC. lease obligation incurred for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- GALECTIN THERAPEUTICS INC. lease obligation incurred for the quarter ending 2025-12-31 was $0.00.
- GALECTIN THERAPEUTICS INC. lease obligation incurred for the quarter ending 2025-09-30 was $0.00.
- GALECTIN THERAPEUTICS INC. lease obligation incurred for fiscal 2025 was $61.00K.
- GALECTIN THERAPEUTICS INC. lease obligation incurred for fiscal 2024 was $0.00.
- GALECTIN THERAPEUTICS INC. lease obligation incurred for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- GALECTIN THERAPEUTICS INC. lease obligation incurred for fiscal 2022 was $111.00K.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|---|
| 2026-06-30 | $127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $127.00K 10-Q · filed 2026-08-14 | $127.00K derived: sum of 3 quarters · filed 2026-08-14 | $127.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $0.00 derived: sum of 3 quarters · filed 2026-05-15 | $0.00 derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $61.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $61.00K 10-Q · filed 2025-11-14 | $61.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $61.00K 10-Q · filed 2026-08-14 | $61.00K derived: sum of 3 quarters · filed 2026-08-14 | $61.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $61.00K 10-Q · filed 2026-05-15 | $61.00K derived: sum of 2 quarters · filed 2026-05-15 | $61.00K derived: sum of 3 quarters · filed 2026-05-15 | $61.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $0.00 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 3 quarters · filed 2025-08-14 | $0.00 derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-05-15 | $0.00 derived: sum of 3 quarters · filed 2025-05-15 | $0.00 derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 10-K · filed 2024-03-29 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $111.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $111.00K 10-Q · filed 2023-11-13 | $111.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $111.00K 10-Q · filed 2023-08-14 | $111.00K derived: sum of 3 quarters · filed 2023-08-14 | $111.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $111.00K 10-Q · filed 2023-05-15 | $111.00K derived: sum of 2 quarters · filed 2023-05-15 | $111.00K derived: sum of 3 quarters · filed 2023-05-15 | $111.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $0.00 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |